HTT

Sodium-dependent serotonin transporter UniProt accession P31645

Serotonin transporter that cotransports serotonin with one Na(+) ion in exchange for one K(+) ion and possibly one proton in an overall electroneutral transport cycle. Transports serotonin across the plasma membrane from the extracellular compartment to the cytosol thus limiting serotonin intercellular signaling (PubMed:10407194, PubMed:12869649, PubMed:21730057, PubMed:27049939, PubMed:27756841, PubMed:34851672). Essential for serotonin homeostasis in the central nervous system.

In the developing somatosensory cortex, acts in glutamatergic neurons to control serotonin uptake and its trophic functions accounting for proper spatial organization of cortical neurons and elaboration of sensory circuits. In the mature cortex, acts primarily in brainstem raphe neurons to mediate serotonin uptake from the synaptic cleft back into the pre-synaptic terminal thus terminating serotonin signaling at the synapse (By similarity). Modulates mucosal serotonin levels in the gastrointestinal tract through uptake and clearance of serotonin in enterocytes.

Required for enteric neurogenesis and gastrointestinal reflexes (By similarity). Regulates blood serotonin levels by ensuring rapid high affinity uptake of serotonin from plasma to platelets, where it is further stored in dense granules via vesicular monoamine transporters and then released upon stimulation (PubMed:17506858, PubMed:18317590). Mechanistically, the transport cycle starts with an outward-open conformation having Na1(+) and Cl(-) sites occupied.

The binding of a second extracellular Na2(+) ion and serotonin substrate leads to structural changes to outward-occluded to inward-occluded to inward-open, where the Na2(+) ion and serotonin are released into the cytosol. Binding of intracellular K(+) ion induces conformational transitions to inward-occluded to outward-open and completes the cycle by releasing K(+) possibly together with a proton bound to Asp-98 into the extracellular compartment. Na1(+) and Cl(-) ions remain bound throughout the transport cycle (PubMed:10407194, PubMed:12869649, PubMed:21730057, PubMed:27049939, PubMed:27756841, PubMed:34851672).

Additionally, displays serotonin-induced channel-like conductance for monovalent cations, mainly Na(+) ions. The channel activity is uncoupled from the transport cycle and may contribute to the membrane resting potential or excitability (By similarity)

Source: UniProt

Monomer or homooligomer (By similarity). Interacts with TGFB1I1 (PubMed:16803896). Interacts with SEC23A, SEC24C and PATJ.

Interacts with NOS1; the interaction may diminish the cell surface localization of SERT in the brain and, correspondingly, reduce serotonin reuptake. Interacts with filamentous actin and STX1A (By similarity). Interacts (via the N-terminus) with STX1A (via the H3 domain); this interaction regulates SLC4A6 channel conductance (By similarity).

Interacts (via C-terminus) with SCAMP2; the interaction is direct and retains transporter molecules intracellularly (PubMed:16870614). Interacts with ITGAV:ITGB3 (PubMed:18317590). Interacts (via C-terminus) with ITGB3; this interaction regulates SLC6A4 trafficking (PubMed:18317590)

Source: UniProt
Cell membrane — Multi-pass membrane protein, Endomembrane system — Multi-pass membrane protein, Endosome membrane — Multi-pass membrane protein, Synapse, Cell junction, focal adhesion, Cell projection, neuron projection
Source: UniProt

Expressed in platelets (at protein level)

Source: UniProt

Click a pathway to open the interactive Reactome viewer.

Pathway list and interactive viewer: Reactome

Synthetic Lethal Network

Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to HTT, aggregated across our SSL data sources. Click any partner node to view that gene’s page.

Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.

BioGRID SLOrth SynLethDB MexDrugs Multi-source
Sources: BioGRID, SLOrth, SynLethDB, MexDrugs

Clinical Trials

Total Trials Found: 1

NCT ID Condition Brief Title Phase Status
NCT00456430 Depression Serotonin Transporter Genetic Variation and Amygdalar Activation Correlates of Antidepressant Response PHASE4 COMPLETED
NCT06082713 Huntington Disease Extracellular Vesicles for HD N/A RECRUITING
NCT04421339 Huntington Disease Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study NA COMPLETED
NCT06873334 Huntington Disease, Huntingtons Disease Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease PHASE2, PHASE3 ACTIVE_NOT_RECRUITING
NCT02717052 Depression, Ketamine Positron Emission Tomography Assessment of Ketamine Binding of the Serotonin Transporter PHASE2 UNKNOWN
NCT01059591 Depressive Disorder and Anxiety Disorders First Study in Humans With GSK424887 PHASE1 COMPLETED
NCT01065220 Transsexualism Sex Steroids and the Serotonin Transporter PHASE4 COMPLETED
NCT05225051 Huntington Disease N- Homocysteinylated Huntingtin in Huntington's Disease NA UNKNOWN
NCT01568307 Major Depressive Disorder Major Depressive Disorder - Understanding The Link Between The Brain And The Heart PHASE4 COMPLETED
NCT01357681 Huntington Disease Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study) PHASE2 COMPLETED